Panagora Asset Management’s Acrivon Therapeutics ACRV Stock Holding History

Panagora Asset Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47K	Buy	+33,814	New	+$59K	﹤0.01%	1151

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Panagora Asset Management's ACRV Position: Q1 2026 in Review

Panagora Asset Management opened a new position in Acrivon Therapeutics (ACRV) in Q1 2026: 33,814 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #1151 among its holdings.

44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Panagora Asset Management held 33,814 shares of Acrivon Therapeutics worth $47K as of Q1 2026.
Acrivon Therapeutics was a new Panagora Asset Management position in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q1 2026, its #1151 holding.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.